167 related articles for article (PubMed ID: 19675882)
41. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
42. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes.
Lazar V; Bidart JM; Caillou B; Mahé C; Lacroix L; Filetti S; Schlumberger M
J Clin Endocrinol Metab; 1999 Sep; 84(9):3228-34. PubMed ID: 10487692
[TBL] [Abstract][Full Text] [Related]
43. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
[TBL] [Abstract][Full Text] [Related]
44. Retinoic acid modulation of thyroid dual oxidase activity in rats and its impact on thyroid iodine organification.
Mühlbauer M; da Silva AC; Marassi MP; Lourenço AL; Ferreira AC; de Carvalho DP
J Endocrinol; 2010 Jun; 205(3):271-7. PubMed ID: 20212023
[TBL] [Abstract][Full Text] [Related]
45. [Estimation of sodium/iodide symporter gene expression (NIS) in thyroid cancer by RT-PCR technique (preliminary study)].
Tosiek M; Pomorski L; Balcerczak E; Mirowski M; Czyz W
Endokrynol Pol; 2005; 56(1):25-9. PubMed ID: 16335670
[TBL] [Abstract][Full Text] [Related]
46. A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma.
Liang JA; Chen CP; Huang SJ; Ho TY; Hsiang CY; Ding HJ; Wu SL
Cancer Lett; 2005 Dec; 230(1):65-71. PubMed ID: 16253762
[TBL] [Abstract][Full Text] [Related]
47. Tumor necrosis factor, ceramide, transforming growth factor-beta1, and aging reduce Na+/I- symporter messenger ribonucleic acid levels in FRTL-5 cells.
Pekary AE; Hershman JM
Endocrinology; 1998 Feb; 139(2):703-12. PubMed ID: 9449644
[TBL] [Abstract][Full Text] [Related]
48. Age-dependent variation of follicular size and expression of iodine transporters in human thyroid tissue.
Faggiano A; Coulot J; Bellon N; Talbot M; Caillou B; Ricard M; Bidart JM; Schlumberger M
J Nucl Med; 2004 Feb; 45(2):232-7. PubMed ID: 14960641
[TBL] [Abstract][Full Text] [Related]
49. Switching from MAPK-dependent to MAPK-independent repression of the sodium-iodide symporter in 2D and 3D cultured normal thyroid cells.
Ingeson-Carlsson C; Nilsson M
Mol Cell Endocrinol; 2013 Dec; 381(1-2):241-54. PubMed ID: 23969277
[TBL] [Abstract][Full Text] [Related]
50. Low expression of sodium iodide symporter identifies aggressive thyroid tumors.
Ward LS; Santarosa PL; Granja F; da Assumpção LV; Savoldi M; Goldman GH
Cancer Lett; 2003 Oct; 200(1):85-91. PubMed ID: 14550956
[TBL] [Abstract][Full Text] [Related]
51. MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner.
Vadysirisack DD; Venkateswaran A; Zhang Z; Jhiang SM
Endocr Relat Cancer; 2007 Jun; 14(2):421-32. PubMed ID: 17639055
[TBL] [Abstract][Full Text] [Related]
52. Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene.
Suzuki K; Mori A; Saito J; Moriyama E; Ullianich L; Kohn LD
Endocrinology; 1999 Nov; 140(11):5422-30. PubMed ID: 10537174
[TBL] [Abstract][Full Text] [Related]
53. Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide.
Josefsson M; Grunditz T; Ohlsson T; Ekblad E
Acta Physiol Scand; 2002 Jun; 175(2):129-37. PubMed ID: 12028133
[TBL] [Abstract][Full Text] [Related]
54. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells.
Dohán O; De la Vieja A; Carrasco N
Mol Endocrinol; 2006 May; 20(5):1121-37. PubMed ID: 16439463
[TBL] [Abstract][Full Text] [Related]
55. [Sodium iodide symporter in physiology and diseases -- the current state of knowledge].
Wolny M; Syrenicz A
Endokrynol Pol; 2007; 58(6):512-21. PubMed ID: 18205108
[TBL] [Abstract][Full Text] [Related]
56. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology.
De La Vieja A; Dohan O; Levy O; Carrasco N
Physiol Rev; 2000 Jul; 80(3):1083-105. PubMed ID: 10893432
[TBL] [Abstract][Full Text] [Related]
57. Journey of the iodide transporter NIS: from its molecular identification to its clinical role in cancer.
Riedel C; Dohán O; De la Vieja A; Ginter CS; Carrasco N
Trends Biochem Sci; 2001 Aug; 26(8):490-6. PubMed ID: 11504625
[TBL] [Abstract][Full Text] [Related]
58. Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells.
Li W; Ain KB
Endocr Relat Cancer; 2010 Jun; 17(2):383-98. PubMed ID: 20228127
[TBL] [Abstract][Full Text] [Related]
59. The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.
Heltemes LM; Hagan CR; Mitrofanova EE; Panchal RG; Guo J; Link CJ
Cancer Gene Ther; 2003 Jan; 10(1):14-22. PubMed ID: 12489024
[TBL] [Abstract][Full Text] [Related]
60. Absence of sodium/iodide symporter gene mutations in differentiated human thyroid carcinomas.
Russo D; Manole D; Arturi F; Suarez HG; Schlumberger M; Filetti S; Derwahl M
Thyroid; 2001 Jan; 11(1):37-9. PubMed ID: 11272095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
